These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11370999)

  • 1. Pharmacological properties of the MPTP analog trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetrahydropyridine and its pyridinium metabolite in mouse brain synaptosomes: a potential visual marker for substrates of MPTP-induced neurotoxicity.
    Klein BG; Kirby ML; Freeborn ER; Bloomquist JR
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):591-608. PubMed ID: 11370999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A.
    Basma AN; Heikkila RE; Nicklas WJ; Giovanni A; Geller HM
    J Neurochem; 1990 Sep; 55(3):870-7. PubMed ID: 2384758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotransformation of the MPTP analog trans-1-methyl-4-[4-dimethylaminophenylethenyl]-1,2,3,6-tetra- hydropyridine to a fluorescent pyridinium metabolite by intact neuroblastoma cells.
    Song X; Ehrich M; Flaherty D; Wang YX; Castagnoli N
    Toxicol Appl Pharmacol; 1996 Apr; 137(2):163-72. PubMed ID: 8661341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2'-methyl-MPTP.
    Sziráki I; Kardos V; Patthy M; Pátfalusi M; Gaál J; Solti M; Kollár E; Singer J
    J Neural Transm Suppl; 1994; 41():207-19. PubMed ID: 7931228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
    Sirinathsinghji DJ; Heavens RP; McBride CS
    Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
    Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
    Sagi Y; Weinstock M; Youdim MB
    J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.
    Finnegan KT; Irwin I; Delanney LE; Langston JW
    J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
    Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity.
    Kinemuchi H; Arai Y; Toyoshima Y
    Neurosci Lett; 1985 Jul; 58(2):195-200. PubMed ID: 3876524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and related compounds on the uptake of [3H]3,4-dihydroxyphenylethylamine and [3H]5-hydroxytryptamine in neostriatal synaptosomal preparations.
    Heikkila RE; Youngster SK; Manzino L; Cabbat FS; Duvoisin RC
    J Neurochem; 1985 Jan; 44(1):310-3. PubMed ID: 3871120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+.
    Shen RS; Abell CW; Gessner W; Brossi A
    FEBS Lett; 1985 Sep; 189(2):225-30. PubMed ID: 3876242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.
    Kindt MV; Youngster SK; Sonsalla PK; Duvoisin RC; Heikkila RE
    Eur J Pharmacol; 1988 Feb; 146(2-3):313-8. PubMed ID: 3131149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat.
    Desole MS; Esposito G; Fresu L; Migheli R; Enrico P; Miele M; De Natale G; Miele E
    Neurosci Lett; 1993 Oct; 161(2):121-3. PubMed ID: 7903798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
    Johannessen JN; Sobotka TJ; Weise VK; Markey SP
    J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of discrepancies in neurotoxic properties among 1-methyl-4-aryl-1,2,3,6-tetrahydropyridines.
    Bachurin SO; Sablin SO; Lermontova NN; Solyakov LS; Dubova LG; Tkachenko SE
    Mol Chem Neuropathol; 1992 Dec; 17(3):189-200. PubMed ID: 1362875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in mice.
    Melamed E; Pikarski E; Goldberg A; Rosenthal J; Uzzan A; Conforti N
    Brain Res; 1986 Dec; 399(1):178-80. PubMed ID: 3492237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent depletion of striatal dopamine and cortical norepinephrine in mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-3-pyridinol (MPTP-3-OL), an analog of MPTP.
    Hemrick-Luecke SK; Robertson DW; Krushinski JH; Fuller RW
    Life Sci; 1992; 50(8):573-82. PubMed ID: 1736028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.